695216-60-5

Upstream product

• 929041-97-4 3-(hydroxymethyl)-5-[methyl(methylsulfonyl)amino]benzoic acid methyl ester 
• 695216-59-2 C₁₃H₁₈N₂O₆S 

Downstream Products

• 876593-44-1 3-((Z)-2-Cyclopropyl-vinyl)-5-(methanesulfonyl-methyl-amino)-benzoic acid methyl ester 
• 876593-45-2 3-((E)-2-Cyclopropyl-vinyl)-5-(methanesulfonyl-methyl-amino)-benzoic acid methyl ester 
• 1067649-16-4 3-(methanesulphonyl-methyl-amino)-5-[(R)-1-(2-methoxy-ethoxy)-3-phenyl-butyl]-benzoic acid 
• 1067649-09-5 3-(methanesulphonyl-methyl-amino)-5-[1-(2-methoxy-ethoxy)-3-phenyl-propyl]-benzoic acid 
• 1067649-18-6 3-((R)-1-hydroxy-3-phenyl-butyl)-5-(methanesulphonyl-methyl-amino)-benzoic acid 
• 1067649-13-1 3-((R)-1-hydroxy-3-phenyl-butyl)-5-(methanesulphonyl-methyl-amino)-benzoic acid methyl ester 
• 1067649-07-3 3-(1-hydroxy-3-phenyl-propyl)-5-(methanesulphonyl-methyl-amino)-benzoic acid methyl ester 
• 929041-98-5 3-(2-cyclopropylvinyl)-5-[methyl(methylsulfonyl)amino]benzoic acid 

Relevant academic research and scientific papers

Conformationally biased P3 amide replacements of β-secretase inhibitors

We have synthesized and evaluated a series of conformationally biased P3 amide replacements based on an isophthalamide lead structure. The studies resulted in the identification of the β-secretase inhibitor 7m which has an in vitro IC50 = 35 nM

β SECRETASE INHIBITOR

Disclosed is a compound represented by the formula (1) below which is useful as a drug for treating Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (1) [In the formula, R1 represents a group represented by the following formula (2): (2) (wherein X represents a nitrogen atom or a group expressed as C(R5); Y represents a nitrogen atom or a group expressed as C(R6); and R5 and R6 independently represent a hydrogen atom or the like) or the like; m represents an integer of 1-6; L1 represents a single bond or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl group or the like; R3 represents a hydrogen atom or the like; L2 represents a single bond or the like; and R4 represents a hydrogen atom, a substituted or unsubstituted aryl group or the like.]

PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment or prevention of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is a